FRAMINGHAM, MA -- (MARKET WIRE) -- May 30, 2007 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) announced that representatives from the company recently met with the United Kingdom regulatory authorities (the MHRA) seeking their input and guidance regarding the nonclinical and clinical issues on the development of IoGen™ as a treatment for moderate to severe cyclic breast pain and tenderness associated with fibrocystic breasts.
